Non-profit Pennsylvania Network Is Expanding Use of Masimo Patient
SafetyNet™, Root® with Radius-7®
and Vital Signs Check to Almost 500 Beds Across 10 Hospitals
BETHLEHEM, Pa.--(BUSINESS WIRE)--Mar. 19, 2019--
St.
Luke’s University Health Network (St. Luke’s) and Masimo (NASDAQ:
MASI) announced today that St. Luke’s, a regional network of 10
hospitals and 320 affiliated sites providing service to 10 counties in
eastern Pennsylvania, is expanding their use of a variety of Masimo
technologies following impressive outcome results at a pilot site.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190319005899/en/
Four years ago, seeking to improve patient safety and reduce morbidity
and mortality in their hospitals, St. Luke’s formed a multidisciplinary
taskforce – comprised of anesthesiologists, nurses, respiratory
specialists, hospital leaders, and others – charged with implementing
changes and tracking outcomes in a pilot location, a 34-bed orthopedic
trauma ward at their hospital in Bethlehem. As part of that program,
which also involved changes in clinical practice and alarm management,
St. Luke’s installed Masimo Patient SafetyNet™, a supplemental remote
monitoring and clinician notification system, in the pilot ward.
Patients were monitored at the bedside using the Masimo Root®
patient monitoring and connectivity hub in conjunction with Masimo
Radius-7® tetherless, wearable Pulse CO-Oximeters®
that continuously monitor patients’ oxygen saturation and pulse rate
using Masimo SET® Measure-through Motion and Low Perfusion™
pulse oximetry. Through Patient SafetyNet, these and other parameters
can be continuously remotely monitored from central view stations and
even smartphones, with the ability to alert clinicians from afar to
possible deterioration in patient condition. In 2016, a year after
implementation of the program, clinicians achieved impressive outcome
and financial results compared to 2015 performance, including a 62%
reduction in mortality, a 36% reduction in naloxone administration, a
23% reduction in the utilization of telemetry, a 26% reduction in
critical care transfers, and an estimated savings of $900,000 in cost
avoidance.
“Because of the unpredictability of which patients will deteriorate,
continuous and in-depth monitoring provides a valuable level of data
that can be acted upon quickly to save lives,” said Aldo Carmona, MD,
Chairman of the Department of Anesthesia and Critical Care and SVP of
Clinical Integration, who leads the initiative. “Constant monitoring of
changes in patient conditions will alert doctors and nurses when gradual
deterioration is sensed, enabling a quicker therapeutic response and
avoiding emergent situations.”
Following the successful pilot program, St. Luke’s expanded use of
Patient SafetyNet to an additional 48 beds across two additional units
on their Bethlehem campus. Now, three years later, the network is again
expanding use of Patient SafetyNet and other Masimo solutions to almost
500 beds in total, so that all eight existing hospitals will have the
technology – and in two hospitals slated to open this year, only Masimo
continuous monitoring technologies will be used outside the ICU.
Monitoring data is now automatically transferred from bedside devices
and Patient SafetyNet to St. Luke’s Epic electronic medical record (EMR)
system, helping improve productivity and reducing the likelihood of
transcription errors.1Vital Signs Check, an application for
Root designed to streamline vital signs measurement workflows and
optimize patient data management, is also being implemented. “With the
higher acuity levels of many hospitalized patients, taking vital signs
over four or eight hours is no longer effective in many cases, and
developing conditions are missed until they become critical threats
sometimes resulting in poor outcomes,” Dr. Carmona said.
Speaking of the ongoing expansion and enhancement of their continuous
monitoring program, Dr. Carmona commented, “This Patient SafetyNet
initiative will be the most important patient safety project I will work
on in my whole career.”
St. Luke’s sought inspiration from another institution’s successful
implementation of continuous monitoring using Masimo SET® and
Patient SafetyNet: Dartmouth-Hitchcock Medical Center in New Hampshire,
where researchers found that continuous monitoring of adult
post-surgical patients using Masimo SET® pulse oximetry on
Masimo bedside devices, in conjunction with Masimo Patient SafetyNet,
resulted in a 65% reduction in rapid response team activations and a 48%
reduction in transfers back to the ICU.2 Over five years,
Dartmouth-Hitchcock achieved their goal of zero preventable deaths or
brain damage due to opioids,3 and over ten years, they
maintained a 50% reduction in unplanned transfers and a 60% reduction in
rescue events, despite increases in patient acuity and occupancy.4
With the monitoring of additional physiological parameters and
integration into EMRs, St. Luke’s initiative is set to provide even more
continuous supplemental monitoring coverage than at Dartmouth-Hitchcock.
Joe Kiani, Founder and CEO of Masimo, said, “We are honored to partner
with St. Luke’s as they continue to expand their patient safety and
monitoring initiatives. Our mission – to improve patient outcomes and
reduce the cost of care – aligns well with their values. Their ongoing
commitment to saving lives through our proven SET® and
Patient SafetyNet technology is a model we hope more and more
institutions will see the benefits of implementing.”
@MasimoInnovates |
#Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown over 100 independent and objective studies to outperform other
pulse oximetry technologies.5 Masimo SET® has also
been shown to help clinicians reduce severe retinopathy of prematurity
in neonates,6 improve CCHD screening in newborns,7
and, when used for continuous monitoring with Masimo Patient SafetyNet™
in post-surgical wards, reduce rapid response activations and costs.2-4
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,8 and is the primary pulse oximetry at 9 of the top 10
hospitals listed in the 2018-19 U.S. News and World Report Best
Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States. The use of the trademark Patient SafetyNet is
under license from University HealthSystem Consortium.
References
|
|
|
|
|
1.
|
|
The Value of Medical Device Interoperability. West Health Institute.
2013.
|
|
|
|
|
2.
|
|
Taenzer AH et al. Impact of pulse oximetry surveillance on rescue
events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
|
|
|
|
|
3.
|
|
Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
|
|
|
|
|
4.
|
|
McGrath SP et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
|
|
|
|
|
5.
|
|
Published clinical studies on pulse oximetry and the benefits of
Masimo SET® can be found on our website at http://www.masimo.com.
Comparative studies include independent and objective studies
which are comprised of abstracts presented at scientific meetings
and peer-reviewed journal articles
|
|
|
|
|
6.
|
|
Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
|
|
|
|
|
7.
|
|
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
|
|
|
|
|
8.
|
|
Estimate: Masimo data on file.
|
|
|
|
|
9.
|
|
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
|
About St. Luke’s
Founded in 1872, St.
Luke’s University Health Network (SLUHN) is a fully integrated,
regional, non-profit network of more than 15,000 employees providing
services at 10 hospitals and over 320 outpatient sites. With annual net
revenue greater than $2 billion, the Network’s service area includes 10
counties: Lehigh, Northampton, Berks, Bucks, Carbon, Montgomery, Monroe
and Schuylkill counties in Pennsylvania and Warren and Hunterdon
counties in New Jersey. Dedicated to advancing medical education, St.
Luke’s is the preeminent teaching hospital in central-eastern
Pennsylvania. In partnership with Temple University, St. Luke’s created
the Lehigh Valley’s first and only regional medical school campus. It
also operates the nation’s longest continuously operating School of
Nursing, established in 1884, and 28 fully accredited graduate medical
educational programs with 226 residents and fellows. St. Luke’s is the
only Lehigh Valley-based health care system with Medicare’s five- and
four-star ratings (the highest) for quality, efficiency and patient
satisfaction. St. Luke’s is both a Leapfrog Group and Healthgrades Top
Hospital. In 2019, three of IBM Watson Health’s 100 Top Hospitals were
St. Luke’s hospitals. St. Luke’s University Hospital has earned the 100
Top Major Teaching Hospital designation from IBM Watson Health seven
times total and five years in a row. St. Luke’s has also been cited by
IBM Watson Health as a 50 Top Cardiovascular Program. Utilizing the Epic
electronic medical record (EMR) system for both inpatient and outpatient
services, the Network is a multi-year recipient of the Most Wired award
recognizing the breadth of the SLUHN’s information technology
applications such as telehealth, online scheduling and online pricing
information. St. Luke’s is also recognized as one of the state’s lowest
cost providers.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Patient SafetyNet™, SET®, Root®,
and Radius-7®. These forward-looking statements are based on
current expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and many
of which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies,
including Masimo Patient SafetyNet, SET®, Root, and Radius-7,
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190319005899/en/
Source: Masimo
Media Contacts:
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com
St. Luke’s
Sam Kennedy, Corporate Communications Director
484-526-4134
Samuel.kennedy@sluhn.org